In p53 wild-type GSCs, HDAC1 depletion has been found to activate STAT3, which may enhance tumor aggressiveness, suggesting that dual targeting of STAT3 and HDAC1 could serve as a potential therapeutic strategy for p53 wild-type GBM [66]. This evidence concerns the gene HDAC1 and neoplasm.